Cargando…

Erratum to: Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomised, open-label, active-controlled study (DOLOMITES)

Detalles Bibliográficos
Autores principales:	Barratt, Jonathan, Andric, Branislav, Tataradze, Avtandil, Schömig, Michael, Reusch, Michael, Valluri, Udaya, Mariat, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951194/ https://www.ncbi.nlm.nih.gov/pubmed/35146511 http://dx.doi.org/10.1093/ndt/gfab349

Ejemplares similares

Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)
por: Barratt, Jonathan, et al.
Publicado: (2021)

Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)
por: Shutov, Evgeny, et al.
Publicado: (2021)

Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)
por: Csiky, Botond, et al.
Publicado: (2021)

Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
por: Barratt, Jonathan, et al.
Publicado: (2021)

Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia
por: Zhu, Xin-Wang, et al.
Publicado: (2021)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Population pharmacokinetics of roxadustat in Japanese dialysis‐dependent chronic kidney disease patients with anaemia
por: Takada, Akitsugu, et al.
Publicado: (2021)

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
por: Barratt, Jonathan, et al.
Publicado: (2023)

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
por: Akizawa, Tadao, et al.
Publicado: (2019)

Lower starting dose of roxadustat in non-dialysis-dependent chronic kidney disease patients with anaemia: a study protocol for a randomised, multicentre, open-label study
por: Li, Ping, et al.
Publicado: (2023)

Roxadustat for CKD-related Anemia in Non-dialysis Patients
por: Coyne, Daniel W., et al.
Publicado: (2020)

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
por: Akizawa, Tadao, et al.
Publicado: (2019)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Erratum to: Differences in quality of life of hemodialysis patients between dialysis centers
por: Mazairac, Albert H. A., et al.
Publicado: (2011)

Erratum to: Guidelines for the labelling of leucocytes with (111)In-oxine
por: Roca, Manel, et al.
Publicado: (2010)

Lower serum uric acid level predicts mortality in dialysis patients: Erratum
Publicado: (2021)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Erratum to: BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study
por: Michallet, Mauricette, et al.
Publicado: (2014)

Erratum to: PREVENTT: preoperative intravenous iron to treat anaemia in major surgery: study protocol for a randomised controlled trial
por: Richards, Toby, et al.
Publicado: (2015)

A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia
por: Yang, Qin, et al.
Publicado: (2021)

Nurse practitioner consultations in primary health care: an observational interaction analysis of social interactions and consultation outcomes – ERRATUM
por: Barratt, Julian, et al.
Publicado: (2018)

Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin
por: Sepah, Yasir J., et al.
Publicado: (2022)

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
por: Provenzano, Robert, et al.
Publicado: (2020)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
por: Hirai, Keiji, et al.
Publicado: (2021)

Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
por: Zhang, Yangyang, et al.
Publicado: (2023)

Erratum to: Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO
por: de Vries, Erik F. J., et al.
Publicado: (2010)

Erratum to: Clearing and Labeling Techniques for Large-Scale Biological Tissues
por: Seo, Jinyoung, et al.
Publicado: (2019)

Erratum for Monsees et al., “Label-Free Raman Microspectroscopy for Identifying Prokaryotic Virocells”
por: Monsees, Indra, et al.
Publicado: (2022)

Erratum Regarding “Cost-Utility of Dialysis in Canada: Hemodialysis, Peritoneal Dialysis, and Nondialysis Treatment of Kidney Failure” (Kidney Med. 2021;3[1]:20-30)
Publicado: (2021)

Erratum to “Optimal Hemodialysis Prescription: Do Children Need More Than a Urea Dialysis Dose?”
por: Fischbach, Michel, et al.
Publicado: (2011)

Erratum to: Multicentre randomized controlled trial comparing ferric(III) carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients
por: Borstlap, WAA, et al.
Publicado: (2015)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
por: Wu, Tong, et al.
Publicado: (2022)

Observations on Anæmia in the Malnad Parts of the Mysore State
Publicado: (1947)

Erratum to: A new F-18 labeled PET tracer for fatty acid imaging
por: Demeure, Fabian, et al.
Publicado: (2014)

A multicenter, open-label, phase III study of Abcertin in Gaucher disease: Erratum
Publicado: (2018)

Erratum to: Temporal changes and risk factors for death from early withdrawal within 12 months of dialysis initiation—a cohort study
por: Chen, Jenny H C, et al.
Publicado: (2022)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Erratum to “Arterial Spin Labeling (ASL) fMRI: Advantages, Theoretical Constrains and Experimental Challenges in Neurosciences”
por: Borogovac, Ajna, et al.
Publicado: (2012)

Erratum: Biodistribution of Cy5-labeled Thiolated and Methylated Chitosan-Carboxymethyl Dextran Nanoparticles in an Animal Model of Retinoblastoma
por: Delrish, Elham, et al.
Publicado: (2022)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
por: Yang, Zhikai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g7hg0ii6q4qnkeck2oc5vf1jic